BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, have announced the publication of results from the Phase II EAGLE clinical trial for BL-1020, a first in class, orally available, GABA-enhanced antipsychotic for the treatment of schizophrenia, showing that BL-1020...